Arrien Pharmaceuticals, LLC.

About us

Home
About us
Company Overview

Company Overview

Arrien Pharmaceuticals is a "FIELDS" technology driven biopharmaceutical company focused on discovery and development of innovative and effective drug candidates for the treatment of human cancers. The company currently has three drug candidates for oncology and two other programs in development for non-oncology indications.

ARN-6039 completed its Phase 1 clinical trials and was partnered with Boston Pharmaceuticals in 2017.

ARN-3261 is a SIK2 inhibitor in development, competed its IND enabling studies, and Licensed. Clinical Phase 1a/1b trial will be initiated in Q1 2021.

"FIELDS" Technology Driven Fragment-Based Drug Discovery to Clinical Candidates.
Pipeline of Targeted Cancer Therapeutics.
Developing Small Molecules for Cancer Immunotherapy.
Accelerating Innovation Through Smart Drug Design to Targeted Medicines.
Deep-Learned target "FIELDS" to novel small molecule leads.

Mission & Values

We believe that our foremost responsibility lies with the millions of patients around the world and our focus is on the discovery and development of new drugs to treat patients where the current therapeutics are inadequate.

About us

"FIELDS" Technology Driven Fragment-Based Drug Discovery to Clinical Candidates.

Pipeline of Targeted Cancer Therapeutics.

Developing Small Molecules for Cancer Immunotherapy.

Accelerating Innovation Through Smart Drug Design to Targeted Medicines.

Deep-Learned target "FIELDS" to novel small molecule leads.

Mission & Values

We believe that our foremost responsibility lies with the millions of patients around the world and our focus is on the discovery and development of new drugs to treat patients where the current therapeutics are inadequate.